NEJM: 压力支持通气或 T 管的自主呼吸试验

NEJM: 压力支持通气或 T 管的自主呼吸试验



Spontaneous-breathing trials can be performed with the use of either pressure-support ventilation (PSV) or a T-piece. Whether PSV trials may result in a shorter time to tracheal extubation than T-piece trials, without resulting in a higher risk of reintubation, among patients who have a high risk of extubation failure is unknown.

可以使用压力支持通气 (PSV) 或 T 管进行自主呼吸试验。在拔管失败高风险的患者中,PSV 试验是否会比 T 管试验更短的气管拔管时间,而不会导致更高的再插管风险,目前尚不清楚。


In this multicenter, open-label trial, we randomly assigned patients who had a high risk of extubation failure (i.e., were >65 years of age or had an underlying chronic cardiac or respiratory disease) to undergo spontaneous-breathing trials performed with the use of either PSV (with a pressure-support level of 8 cm of water and no positive end-expiratory pressure) or a T-piece. The primary outcome was the total time without exposure to invasive ventilation (reported as the number of ventilator-free days) at day 28 after the initial spontaneous-breathing trial. Secondary outcomes included extubation within 24 hours and extubation within 7 days after the initial spontaneous-breathing trial, as well as reintubation within 7 days after extubation.

在这项多中心、开放标签试验中,我们将拔管失败风险高的患者(即 >65 岁或患有潜在的慢性心脏或呼吸系统疾病)随机分配到使用PSV(压力支持水平为 8 厘米水柱且无呼气末正压)或 T 管。主要结果是在最初的自主呼吸试验后第 28 天未暴露于有创通气的总时间(报告为无呼吸机天数)。次要结局包括在初始自主呼吸试验后 24 小时内拔管和 7 天内拔管,以及拔管后 7 天内重新插管。

NEJM: 压力支持通气或 T 管的自主呼吸试验


A total of 969 patients (484 in the PSV group and 485 in the T-piece group) were included in the analysis. At day 28, the median number of ventilator-free days was 27 (interquartile range, 24 to 27) in the PSV group and 27 (interquartile range, 23 to 27) in the T-piece group (difference, 0 days; 95% confidence interval [CI], −0.5 to 1; P=0.31). Extubation was performed within 24 hours in 376 patients (77.7%) in the PSV group and in 350 patients (72.2%) in the T-piece group (difference, 5.5 percentage points; 95% CI, 0.01 to 10.9), and extubation was performed within 7 days in 473 patients (97.7%) and 458 patients (94.4%), respectively (difference, 3.3 percentage points; 95% CI, 0.8 to 5.9). Reintubation was performed in 72 of 481 patients (14.9%) in the PSV group and in 65 of 477 patients (13.6%) in the T-piece group (difference, 1.3 percentage points; 95% CI, −3.1 to 5.8). Cardiac or respiratory arrest was a reason for reintubation in 9 patients (3 in the PSV group and 6 in the T-piece group).

共有 969 名患者(PSV 组 484 名,T 管组 485 名)被纳入分析。在第 28 天,PSV 组的中位无呼吸机天数为 27(四分位距,24 至 27),T 管组为 27 天(四分位距,23 至 27)(差异,0 天;95%置信区间 [CI],-0.5 到 1;P=0.31)。PSV 组 376 例患者(77.7%)和 T 管组 350 例患者(72.2%)在 24 小时内拔管(差异,5.5 个百分点;95% CI,0.01 至 10.9),拔管是分别有 473 名患者 (97.7%) 和 458 名患者 (94.4%) 在 7 天内进行了检查(差异,3.3 个百分点;95% CI,0.8 至 5.9)。PSV 组 481 名患者中的 72 名(14.9%)和 T 管组 477 名患者中的 65 名(13.6%)进行了再插管(差异,1. 3个百分点;95% CI,-3.1 至 5.8)。心脏或呼吸停止是 9 名患者(PSV 组 3 名和 T 管组 6 名)重新插管的原因。

NEJM: 压力支持通气或 T 管的自主呼吸试验
NEJM: 压力支持通气或 T 管的自主呼吸试验
NEJM: 压力支持通气或 T 管的自主呼吸试验


Among patients who had a high risk of extubation failure, spontaneous-breathing trials performed with PSV did not result in significantly more ventilator-free days at day 28 than spontaneous-breathing trials performed with a T-piece. (Supported by the French Ministry of Health; TIP-EX number, NCT04227639. opens in new tab.)

在拔管失败高风险的患者中,与使用 T 管进行的自主呼吸试验相比,使用 PSV 进行的自主呼吸试验在第 28 天没有显着增加无呼吸机天数。(由法国卫生部提供支持;TIP-EX 编号为NCT04227639 。)


    打赏 微信扫一扫 微信扫一扫 支付宝扫一扫 支付宝扫一扫
    上一篇 2022年10月29日 01:05
    下一篇 2022年11月6日 08:22